Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Aug;64(2):221–226. doi: 10.1038/bjc.1991.280

Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukaemia in mice.

A Kiue 1, T Sano 1, A Naito 1, M Okumura 1, K Kohno 1, M Kuwano 1
PMCID: PMC1977534  PMID: 1892749

Abstract

We recently reported that six 1,4-dihydropyridine derivatives out of 57 screened effectively over-came vincristine (VCR)-resistance in VCR-resistant (P388/VCR) leukaemia-bearing mice when the dihydropyridines and VCR were administered intraperitoneally (i.p.). Furthermore, among the six dihydropyridine derivatives, two compounds, NK-250 and NK-252, most effectively overcame VCR-resistance while exhibiting relatively low calcium antagonistic activity and toxicity. In this study, we examined whether NK-250 and NK-252 could potentiate the antitumour activities of etoposide in mice with drug-sensitive (P388/S) or VCR-resistant (P388/VCR) leukaemia cells when the anticancer agents and tumour cells were administered by various routes. In both groups of mice inoculated i.p. with P388/S- and P388/VCR-leukaemia cells, the oral (p.o.) administration of NK-250 combined with i.p. or intravenously (i.v.) administration of etoposide (ip-po-ip trials and ip-po-iv trials) dramatically potentiated the antitumour activity of etoposide. Although etoposide alone was less effective in treating mice inoculated i.v. with P388/S- and P388/VCR-leukaemia cells, p.o. administration of NK-250 combined with i.p. or i.v. administration of etoposide (iv-po-ip trials and iv-po-iv trials) potentiated the antitumour activity of etoposide to similar levels as in treating mice inoculated i.p. with leukaemia cells. These 1,4-dihydropyridines were therefore highly effective in potentiating anticancer drugs against both drug-sensitive and drug-resistant tumours.

Full text

PDF
221

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama S., Yoshimura A., Kikuchi H., Sumizawa T., Kuwano M., Tahara Y. Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells. Mol Pharmacol. 1989 Nov;36(5):730–735. [PubMed] [Google Scholar]
  2. Beck W. T. The cell biology of multiple drug resistance. Biochem Pharmacol. 1987 Sep 15;36(18):2879–2887. doi: 10.1016/0006-2952(87)90198-5. [DOI] [PubMed] [Google Scholar]
  3. Bell D. R., Gerlach J. H., Kartner N., Buick R. N., Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol. 1985 Mar;3(3):311–315. doi: 10.1200/JCO.1985.3.3.311. [DOI] [PubMed] [Google Scholar]
  4. Bradley G., Juranka P. F., Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta. 1988 Aug 3;948(1):87–128. doi: 10.1016/0304-419x(88)90006-6. [DOI] [PubMed] [Google Scholar]
  5. Cornwell M. M., Safa A. R., Felsted R. L., Gottesman M. M., Pastan I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci U S A. 1986 Jun;83(11):3847–3850. doi: 10.1073/pnas.83.11.3847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dalton W. S., Grogan T. M., Meltzer P. S., Scheper R. J., Durie B. G., Taylor C. W., Miller T. P., Salmon S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989 Apr;7(4):415–424. doi: 10.1200/JCO.1989.7.4.415. [DOI] [PubMed] [Google Scholar]
  7. Danks M. K., Yalowich J. C., Beck W. T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 1987 Mar 1;47(5):1297–1301. [PubMed] [Google Scholar]
  8. Fojo A. T., Ueda K., Slamon D. J., Poplack D. G., Gottesman M. M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987 Jan;84(1):265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gerlach J. H., Bell D. R., Karakousis C., Slocum H. K., Kartner N., Rustum Y. M., Ling V., Baker R. M. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol. 1987 Sep;5(9):1452–1460. doi: 10.1200/JCO.1987.5.9.1452. [DOI] [PubMed] [Google Scholar]
  10. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  11. Kamiwatari M., Nagata Y., Kikuchi H., Yoshimura A., Sumizawa T., Shudo N., Sakoda R., Seto K., Akiyama S. Correlation between reversing of multidrug resistance and inhibiting of [3H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydropyridine analogues in a human cell line. Cancer Res. 1989 Jun 15;49(12):3190–3195. [PubMed] [Google Scholar]
  12. Kiue A., Sano T., Naito A., Inada H., Suzuki K., Okumura M., Kikuchi J., Sato S., Takano H., Kohno K. Reversal by two dihydropyridine compounds of resistance to multiple anticancer agents in mouse P388 leukemia in vivo and in vitro. Jpn J Cancer Res. 1990 Oct;81(10):1057–1064. doi: 10.1111/j.1349-7006.1990.tb03346.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kiue A., Sano T., Suzuki K., Inada H., Okumura M., Kikuchi J., Sato S., Kohno K., Kuwano M. Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents. Cancer Res. 1990 Jan 15;50(2):310–317. [PubMed] [Google Scholar]
  14. Ma D. D., Scurr R. D., Davey R. A., Mackertich S. M., Harman D. H., Dowden G., Isbister J. P., Bell D. R. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet. 1987 Jan 17;1(8525):135–137. doi: 10.1016/s0140-6736(87)91969-6. [DOI] [PubMed] [Google Scholar]
  15. Nakagawa M., Akiyama S., Yamaguchi T., Shiraishi N., Ogata J., Kuwano M. Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line. Cancer Res. 1986 Sep;46(9):4453–4457. [PubMed] [Google Scholar]
  16. Nakagawara A., Kadomatsu K., Sato S., Kohno K., Takano H., Akazawa K., Nose Y., Kuwano M. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res. 1990 May 15;50(10):3043–3047. [PubMed] [Google Scholar]
  17. Nogae I., Kohno K., Kikuchi J., Kuwano M., Akiyama S., Kiue A., Suzuki K., Yoshida Y., Cornwell M. M., Pastan I. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem Pharmacol. 1989 Feb 1;38(3):519–527. doi: 10.1016/0006-2952(89)90393-6. [DOI] [PubMed] [Google Scholar]
  18. Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987 May 28;316(22):1388–1393. doi: 10.1056/NEJM198705283162207. [DOI] [PubMed] [Google Scholar]
  19. Safa A. R., Felsted R. L. Specific Vinca alkaloid-binding polypeptides identified in calf brain by photoaffinity labeling. J Biol Chem. 1987 Jan 25;262(3):1261–1267. [PubMed] [Google Scholar]
  20. Shinoda H., Inaba M., Tsuruo T. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52. Cancer Res. 1989 Apr 1;49(7):1722–1726. [PubMed] [Google Scholar]
  21. Shiraishi N., Akiyama S., Nakagawa M., Kobayashi M., Kuwano M. Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Res. 1987 May 1;47(9):2413–2416. [PubMed] [Google Scholar]
  22. Slater L. M., Murray S. L., Wetzel M. W., Sweet P., Stupecky M. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother Pharmacol. 1986;16(1):50–54. doi: 10.1007/BF00255285. [DOI] [PubMed] [Google Scholar]
  23. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 May;41(5):1967–1972. [PubMed] [Google Scholar]
  24. Yalowich J. C., Ross W. E. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res. 1984 Aug;44(8):3360–3365. [PubMed] [Google Scholar]
  25. Yalowich J. C., Ross W. E. Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res. 1985 Apr;45(4):1651–1656. [PubMed] [Google Scholar]
  26. Yalowich J. C., Zucali J. R., Gross M., Ross W. E. Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res. 1985 Oct;45(10):4921–4924. [PubMed] [Google Scholar]
  27. Yamaguchi T., Nakagawa M., Shiraishi N., Yoshida T., Kiyosue T., Arita M., Akiyama S., Kuwano M. Overcoming drug resistance in cancer cells with synthetic isoprenoids. J Natl Cancer Inst. 1986 May;76(5):947–953. [PubMed] [Google Scholar]
  28. Yoshinari T., Iwasawa Y., Miura K., Takahashi I. S., Fukuroda T., Suzuki K., Okura A. Reversal of multidrug resistance by new dihydropyridines with lower calcium antagonistic activity. Cancer Chemother Pharmacol. 1989;24(6):367–370. doi: 10.1007/BF00257444. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES